Sudden appearance of idioventricular rhythm during inhalational induction with halothane in a child with congenital cataract
Sir, An 11-year-old American Society of Anesthesiologists I female child with bilateral congenital cataract was scheduled for lens extraction under general anesthesia. Inhalational induction was done with halothane, oxygen, nitrous oxide using a semiclosed circle system (fresh gas flows of 6L/min). The child was asked to take deep breaths and halothane was stepped up in increments of 0.5% every two to three breaths. As the anesthetic depth increased her ventilation was gently assisted, at an inspired halothane concentration of 2.0%, an accelerated idioventricular rhythm at a rate of 80 beats/min was observed on the monitor at end-tidal carbon dioxide (ETCO 2 ) concentration of 33 mm Hg [ Figure 1 ]. Normal sinus rhythm reappeared when the child was awakened using 100% oxygen. Detailed history and re-examination including a 12 lead EKG and echocardiography did not reveal any cardiac abnormality. It was then noticed that she had shortened metatarsals in both feet [ Figure 2 ] and a short stature (123 cm). This led to the presumptive diagnosis of Albrights' hereditary osteodystrophy (pseudohypoparathyroidism) or Turner's syndrome. On biochemical investigation the serum calcium levels (8.5 mg %), phosphate (4.8 mg %), alkaline phosphatase (594 IU/L), follicular stimulating hormone and parathormone levels were normal. As she was terrified of needles and sevoflurane was unavailable, subsequent anesthetic induction was also with halothane. The idioventricular rhythm reappeared on spontaneous ventilation (ETCO 2 35 mm Hg) at an inspired halothane concentration of 2.5% but on administration of atropine (0.1 mg IV), sinus tachycardia occurred. A day later intraocular lens displacement necessitated re-surgery. As an intravenous cannula was in situ, anesthesia was induced using thiopentone, pethidine and vecuronium. Maintenance with oxygen, nitrous oxide, isoflurane was not accompanied by any dysrhythmia though the heart rate decreased to 64 beats/min.
Presence of anatomic features of pseudohypoparathyroidism with normal parathormone and calcium levels is termed pseudo-pseudohypoparathyroidism. [1] Transient decrease in ionized calcium without change in total serum calcium has been observed in these patients and may be caused by hyperventilation during induction resulting in respiratory alkalosis. [1, 2] Depolarization in the slow response fibers of the sino atrial (SA) and atrio ventricular (AV) nodes occurs due to the inward calcium current. Halothane inhibits this calcium influx, decelerates SA node discharge and prolongs AV node conduction which may predispose patients to develop sinus bradycardia, nodal rhythm, supraventricular or ventricular ectopics. [3] The simultaneous decrease in ionized calcium could have precipitated the idioventricular rhythm in our patient. Isoflurane has a less depressant effect on slow inward calcium current and intracellular calcium accumulation than halothane. [3] This may explain the absence of dysrhythmia with it.
Accelerated idioventricular rhythm or slow ventricular tachycardia (VT) consists of uniform widened QRS complexes at 60-100 beats/min caused by abnormal automaticity of a supraventricular or ventricular focus. It has been observed following acute myocardial infarction, with digitalis toxicity, during cardiac surgery, in patients with rheumatic heart disease or cardiomyopathy but rarely progresses to rapid VT or ventricular fibrillation. [4] Though usually not associated with hemodynamic instability in the absence of left ventricular dysfunction the sudden appearance of this dysrhythmia in a normal child required workup. Atropine administration resulted in accelerating sinoatrial (SA) discharge suppressing this arrhythmia. Lignocaine may prolong atrioventricular (AV) conduction and perpetuate the rhythm and is therefore not recommended. [4] On using Naranjo's adverse drug reaction probability scale we obtained a score of 10 which makes halothane a definite cause for the event.
[5] The dysrhythmia occurred after halothane administration (+2), once halothane was washed out using 100% oxygen normal sinus rhythm reappeared (+1). The idioventricular rhythm (IVR) appeared on first and subsequent induction with halothane (+1),(+2). The IVR did not occur with intravenous induction and isoflurane administration (+1). Though alternative causes of IVR are known e.g. myocardial infarction they were ruled out in this 11-year-old child (+2). The dysrhythmia was objectively recorded on an EKG trace (+1).
The diagnostic features of Albright's hereditary osteodystrophy are shortened third and fourth metacarpals or metatarsals (92%), short stature (76%), round facies (71%) and obesity (61%) and the presence of these features should alert an anesthesiologist about the presence of this syndrome even in the absence of hypocalcemia. [6] In conclusion we report the occurrence of an 
Possible ifosfamide-induced panic attacks
Sir, The anticancer drug ifosfamide is associated with 5-30% incidence of central nervous system toxicity. [1] Manifestations range from somnolence, confusion and agitation, through delusions, hallucinations and psychosis to even seizures and coma. [2, 3] These neuropsychiatric complications are usually of acute onset and subside within 48-72 h, although persistent psychopathological symptoms, irreversible encephalopathy, and even neurotoxic deaths have been recorded. [2, 3] Even though anxiety is known to be part of ifosfamide-induced neurotoxicity, panic attacks are yet to be documented. We report two cases of suspected ifosfamide-induced panic attacks.
Case 1:
A 47-year-old man with arsenic-induced carcinoma of the hard palate and positive neck nodes was started on ifosfamide (2 g IV on Days 1 and 2; followed by 1 g IV on Day 3) and cisplatin (50 mg IV on Days 1, 2 amd 3) combination chemotherapy. The first cycle was given between 04.11.2006 to 06.11.2006, the second between 02.12.2006 to 04.12.2006, and the patient discharged thereafter. Two weeks later, he presented in the outpatient department (OPD) with a seven-day history of multiple episodes of sudden onset palpitation, breathlessness, sweating, intense fear and sensation of 'impending doom'. The episodes were unpredictable and lasted for 10-15 min each.
We witnessed one such episode during which, apart from tachycardia, vital signs were satisfactory. Systemic examination was also normal, except that the patient was highly anxious and sweating profusely. Panic attack was provisionally diagnosed and alprazolam 0.5 mg twice daily, atenolol 50 mg once daily and diazepam 5 mg at bedtime started. The attacks were controlled within a week but recurred on the third cycle (between 25.12.2006 to 27.12.2006). This time, investigations revealed normal blood glucose, thyroid status, ECG and echocardiography. The recurrent episode was controlled by the same medicines as earlier and these were continued during the last two cycles of chemotherapy. No further attacks occurred.
Case 2:
A 32-year-old woman with maxillary antrum carcinoma received ifosfamide (2 g IV on Day 1 followed by 1 g IV on Day 2) and cisplatin (80 mg IV on Day 1) combination. On the morning after the first day of chemotherapy (23.07.2007), she complained of pounding heartbeat, breathlessness and a sensation of 'impending doom'. On examination, pulse was 90 bpm and the patient anxious, trembling and sweating profusely. This episode resolved spontaneously in about 15 min. The second day's chemotherapy was administered and the patient discharged next morning with advice to take alprazolam 0.5 mg at bedtime for three weeks and relevant laboratory workup. One week later she visited the OPD. Panic symptoms had not recurred and tests ruled out cardiac or endocrine pathology.
As per DSM IV criteria, 'panic attack' can be clinically diagnosed if there is a discrete period of intense fear in which four or more out of 13 listed symptoms develop abruptly and peak within 10 min. Our cases satisfied the criteria. The sensorium was clear during the witnessed attacks. As per US National Cancer Institute Common Terminology Criteria for Adverse Events Version 3, the severity of both cases qualifies as moderate (Grade 2) under the neurological mood alteration category. Interestingly, apart from the panic features, other neuropsychiatric symptoms (including hallucinations) were not reported at any point of time. Neither patient gave history of substance abuse, psychiatric illness or major stressful events in the recent past.
The events were 'Probable/Likely' with respect to ifosfamide as the causal drug by the World Health Organization-Uppsala Monitoring Centre criteria. [4] Although both subjects received ifosfamide-cisplatin combination, only ifosfamide is known to cause neuropsychiatric symptoms. Cisplatin neurotoxicity manifests as peripheral neuropathy, sensorineural deafness or optic neuritis but not as neuropsychiatric symptoms. Besides the anticancer drugs, both patients received mesna uroprotection (400 mg of mesna IV/g of ifosfamide) and premedication with dexamethasone (8 mg IV) and ondansetron (12 mg IV). These are also not likely to cause panic attacks. Neither subject received cranial irradiation therapy.
Ifosfamide neurotoxicity is known to exhibit some dosedependence, although relatively lower doses of 3 g/m 2 /cycle have been reported to cause psychiatric symptoms including anxiety-depression and hallucinations. [2] Extrapyramidal toxicity has been reported at 5 g/m 2 /cycle [1] and visual and
